ABSTRACT
Background Age-related macular degeneration (AMD) is a leading cause of blindness in the industrialised world and is projected to affect >280 million people worldwide by 2040. Aiming to identify causal factors and potential therapeutic targets for this common condition, we designed and undertook a phenome-wide Mendelian randomisation (MR) study.
Methods We evaluated the effect of 4,591 exposure traits on early AMD using univariable MR. Statistically significant results were explored further using: validation in an advanced AMD cohort; MR Bayesian model averaging (MR-BMA); and multivariable MR.
Results Overall, 44 traits were found to be putatively causal for early AMD in univariable analysis. Serum proteins that were found to have significant relationships with AMD included S100-A5 (odds ratio [OR]=1.07, p-value=6.80E-06), cathepsin F (OR=1.10, p-value=7.16E-05) and serine palmitoyltransferase 2 (OR=0.86, p-value=1.00E-03). Univariable MR analysis also supported roles for complement and immune cell traits. Although numerous lipid traits were found to be significantly related to AMD, MR-BMA suggested a driving causal role for serum sphingomyelin (marginal inclusion probability [MIP]=0.76; model-averaged causal effect [MACE]=0.29).
Conclusions The results of this MR study support several putative causal factors for AMD and highlight avenues for future translational research.
Funding This project was funded by the Wellcome Trust (224643/Z/21/Z); the University of Manchester’s Wellcome Institutional Strategic Support Fund (Wellcome ISSF) grant (204796/Z/16/Z); the UK National Institute for Health Research (NIHR) Academic Clinical Fellow and Clinical Lecturer Programmes; Retina UK and Fight for Sight (GR586); the Australian National Health and Medical Research Council (NHMRC) (1150144).
IMPACT STATEMENT A phenome-wide Mendelian randomisation analysis revealed a causal link between age-related macular degeneration and a number of lipid, complement, immune cell, and serum protein traits, highlighting potential treatment targets.
Competing Interest Statement
TA is involved on advisory boards and has received grants and speaker fees from Allergan, Novartis, Bayer, Roche, Bausch and Lomb, Heidelberg, Topcon and Canon. SM receives Australian NHMRC funding (Fellowship,Program grant) and is a Cofounder of Seonix Bio Ltd. TJ is funded by the NIHR and a Wellcome Trust Wellcome Institutional Strategic Support Fund for Causal Inference GB is funded by a Wellcome Trust Wellcome Institutional Strategic Support Fund for Causal Inference, the Wellcome trust Transforming Genomic Medicine Initiative (TGMI) grant and the Retina UK & Fight for Sight IRDC grant. PS is funded by a Wellcome Trust Career Development Fellowship. JCK is funded by Wellcome Trust fellowship [216596/Z/19/Z]. The remaining authors have no declarations.
Funding Statement
This project was funded by the Wellcome Trust (224643/Z/21/Z); the University of Manchester Wellcome Institutional Strategic Support Fund (Wellcome ISSF) grant (204796/Z/16/Z); the UK National Institute for Health Research (NIHR) Academic Clinical Fellow and Clinical Lecturer Programmes; Retina UK and Fight for Sight (GR586); the Australian National Health and Medical Research Council (NHMRC) (1150144).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The data utilised in this study was publicly available, in the form of genome wide association study summary statistics. Exposure data utilised in this study is available via the TwoSampleMR R package.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Restructuring of the abstract. Additional methodological detail added. Small alterations to formatting of included tables.
Data Availability
All data generated by this study are available via the supplementary content.
